You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

ACOG MEMBER SUBSCRIPTION ACCESS

If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription.

Bartholin Gland Carcinoma.

COPELAND, LARRY J. MD; SNEIGE, NOUR MD; GERSHENSON, DAVID M. MD; McGUFFEE, VIRGIE B. MA; ABDUL-KARIM, FADI MD; RUTLEDGE, FELIX N. MD
Obstetrics & Gynecology:
Bartholin Gland Carcinoma: PDF Only
Abstract

: Bartholin gland tumors are rare and management recommendations have been based on limited information. This report summarizes a 30-year clinical experience involving Bartholin gland carcinoma in 36 patients whose five-year survival rate was 84%. FIGO stages of the 36 tumors were stage I, nine; stage II, 15; stage III, ten; and stage IV, two. Cell types were: squamous, 27 (three nonkeratinizing with areas of a transitional component); adenomatous, six; adenoid cystic, two; and adenosquamous, one. Fourteen of 30 (47%) patients with lymph node dissections had nodal metastases and 11 remain disease-free. Disease recurred in nine patients (six local, two distant, one local and distant) and four were treated successfully. One of 14 (7%) patients receiving radiation and six of 22 (27%) patients not receiving radiation developed local recurrences. Wide excision (often necessitating a radical hemivulvectomy), ipsilateral inguinal lymphadenectomy, and adjunctive irradiation to the vulva and regional lymph nodes produced excellent results. (Obstet Gynecol 67:794, 1986)

(C) 1986 The American College of Obstetricians and Gynecologists